Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Senti Biosciences, Inc. (SNTI : NSDQ)
 
 • Company Description   
Senti Biosciences Inc. is a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform. Senti Biosciences Inc., formerly known as Dynamics Special Purpose Corp., is based in SOUTH SAN FRANCISCO, Calif.

Number of Employees: 34

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.04 Daily Weekly Monthly
20 Day Moving Average: 4,566,821 shares
Shares Outstanding: 26.29 (millions)
Market Capitalization: $27.34 (millions)
Beta: 2.13
52 Week High: $5.10
52 Week Low: $1.04
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -53.15% -53.07%
12 Week -45.26% -46.15%
Year To Date 0.00% 0.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2 CORPORATE DRIVE FIRST FLOOR
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-239-2030
fax: -
investors@sentibio.com http://www.sentibio.com
 
 • General Corporate Information   
Officers
Timothy Lu - Chief Executive Officer and President
Deborah Knobelman - Chief Financial Officer and Head of Corporate Deve
Frances D. Schulz - Director
Donald Tang - Director
Brenda Cooperstone - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 81726A209
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/19/26
Share - Related Items
Shares Outstanding: 26.29
Most Recent Split Date: 7.00 (0.10:1)
Beta: 2.13
Market Capitalization: $27.34 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.42 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.24 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/19/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.35
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 89.06%
vs. Previous Quarter: -23.21%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
12/31/25 - -
09/30/25 - -197.68
06/30/25 - -223.98
ROA
12/31/25 - -
09/30/25 - -63.05
06/30/25 - -76.02
Current Ratio
12/31/25 - -
09/30/25 - 1.51
06/30/25 - 3.26
Quick Ratio
12/31/25 - -
09/30/25 - 1.51
06/30/25 - 3.26
Operating Margin
12/31/25 - -
09/30/25 - -
06/30/25 - -
Net Margin
12/31/25 - -
09/30/25 - -
06/30/25 - -
Pre-Tax Margin
12/31/25 - -
09/30/25 - -
06/30/25 - -
Book Value
12/31/25 - -
09/30/25 - 0.31
06/30/25 - 0.95
Inventory Turnover
12/31/25 - -
09/30/25 - -
06/30/25 - -
Debt-to-Equity
12/31/25 - -
09/30/25 - 0.00
06/30/25 - 0.00
Debt-to-Capital
12/31/25 - -
09/30/25 - 0.00
06/30/25 - 0.00
 

Powered by Zacks Investment Research ©